These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38678954)

  • 1. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer.
    Xi Y; Li T; Xi Y; Zeng X; Miao Y; Guo R; Zhang M; Li B
    Cancer Cell Int; 2022 Sep; 22(1):271. PubMed ID: 36050724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
    Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis.
    Zeng Z; Zhao Y; Chen Q; Zhu S; Niu Y; Ye Z; Hu P; Chen D; Xu P; Chen J; Hu C; Hu Y; Xu F; Tang J; Wang F; Han S; Huang M; Wang C; Zhao G
    Oncogene; 2021 Sep; 40(36):5505-5517. PubMed ID: 34294845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
    Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q
    J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
    Li T; Tao Z; Zhu Y; Liu X; Wang L; Du Y; Cao J; Wang B; Zhang J; Hu X
    Cell Death Dis; 2021 Jul; 12(7):684. PubMed ID: 34238922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
    Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
    Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer.
    Qing L; Li Q; Yang Y; Xu W; Wang Y; Li R; You C; Dong Z
    Mol Carcinog; 2024 Jul; 63(7):1303-1318. PubMed ID: 38634741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
    Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
    Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
    Xi Y; Yuan P; Li T; Zhang M; Liu MF; Li B
    Cancer Lett; 2020 Jun; 479():112-122. PubMed ID: 32200037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway.
    Wang H; Zhao L; Zhu LT; Wang Y; Pan D; Yao J; You QD; Guo QL
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E107-18. PubMed ID: 23761018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
    Xu Z; Zhang B; Liao Z; Gou S
    Bioorg Med Chem; 2021 Jul; 41():116214. PubMed ID: 33992863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
    Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
    Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
    Jang SI; Fang S; Baek YY; Lee DH; Na K; Lee SY; Lee DK
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
    Cui J; Guo Y; Wu H; Xiong J; Peng T
    Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.